Literature DB >> 22421230

Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes.

Steven P Marso1, Nestor Mercado, Akiko Maehara, Giora Weisz, Gary S Mintz, John McPherson, François Schiele, Dariusz Dudek, Martin Fahy, Ke Xu, Alexandra Lansky, Barry Templin, Zhen Zhang, Bernard de Bruyne, Patrick W Serruys, Gregg W Stone.   

Abstract

OBJECTIVES: The goal of this study was to characterize the extent and composition of coronary atherosclerosis in patients with diabetes mellitus or the metabolic syndrome (Met Syn) presenting with acute coronary syndromes (ACS).
BACKGROUND: Diabetes and Met Syn patients have increased rates of major adverse cardiac events (MACE), yet a systematic description of nonculprit lesions for these high-risk groups is incomplete.
METHODS: In the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study, ACS patients underwent 3-vessel quantitative coronary angiography, grayscale, and radiofrequency intravascular ultrasound after successful percutaneous coronary intervention (PCI). Subsequent MACE (cardiac death or arrest, myocardial infarction, or rehospitalization for unstable or progressive angina) were adjudicated to the originally treated culprit versus untreated nonculprit lesions in 3 patient groups: 1) diabetes; 2) Met Syn; and 3) neither. Median length of follow-up was 3.4 years.
RESULTS: Of 673 patients, 119 (17.7%) had diabetes and 239 (35.5%) had Met Syn. The cumulative 3-year MACE rate was 29.4% in patients with diabetes, 21.3% with Met Syn, and 17.4% with neither (p = 0.03). MACE adjudicated to untreated nonculprit lesions occurred in 18.7%, 11.7%, and 9.7% of patients, respectively (p = 0.06). Nonculprit lesions in diabetes and Met Syn patients were longer and had greater plaque burden, smaller lumen areas, with greater necrotic core and calcium content. Diabetes and Met Syn patients with future MACE had greater necrotic core and calcification compared with the normal cardiometabolic group.
CONCLUSIONS: In this PCI ACS population, patients with diabetes and Met Syn had higher 3-year MACE rates. Lesion length, plaque burden, necrotic core, and calcium content were significantly greater among nonculprit lesions of patients with diabetes and Met Syn, but only necrotic core and calcium were significantly greater in the nonculprit lesions of patients with a future MACE in this exploratory analysis.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22421230     DOI: 10.1016/j.jcmg.2012.01.008

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  35 in total

1.  Role of Akt/protein kinase B in the activity of transcriptional coactivator p300.

Authors:  J Chen; S S Halappanavar; J R St-Germain; B K Tsang; Q Li
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

2.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

Review 3.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

Review 4.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

5.  Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.

Authors:  Arwa Younis; Anan Younis; Boaz Tzur; Yael Peled; Nir Shlomo; Ilan Goldenberg; Enrique Z Fisman; Alexander Tenenbaum; Robert Klempfner
Journal:  Cardiovasc Diabetol       Date:  2016-10-28       Impact factor: 9.951

Review 6.  Physiological Assessment of Coronary Lesions in 2020.

Authors:  Mohsin Chowdhury; Eric A Osborn
Journal:  Curr Treat Options Cardiovasc Med       Date:  2020-01-15

Review 7.  Cardiovascular consequences of metabolic syndrome.

Authors:  Johnathan D Tune; Adam G Goodwill; Daniel J Sassoon; Kieren J Mather
Journal:  Transl Res       Date:  2017-01-09       Impact factor: 7.012

Review 8.  Mitochondrial regulation of diabetic vascular disease: an emerging opportunity.

Authors:  Michael E Widlansky; R Blake Hill
Journal:  Transl Res       Date:  2018-08-04       Impact factor: 7.012

9.  Impact of metabolic syndrome on myocardial injury and clinical outcome after percutaneous coronary intervention.

Authors:  J Li; S-J Song; J-P Xu; X-Z Zhao; Z-W Xu; X-J Sun; L-F Wang; X-C Yang
Journal:  Herz       Date:  2014-10-26       Impact factor: 1.443

Review 10.  Imaging of coronary atherosclerosis in various susceptible groups.

Authors:  Ravi Kiran Munnur; Nitesh Nerlekar; Dennis T L Wong
Journal:  Cardiovasc Diagn Ther       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.